Breaking News, Collaborations & Alliances

Biocytogen Enters Global Licensing Agreement with Merck

Merck KGaA, Darmstadt, Germany will have full access to Biocytogen’s RenMice platform to discover and develop fully human antibody therapeutics.

Author Image

By: Charlie Sternberg

Associate Editor

Biocytogen Pharmaceuticals Co., Ltd. has entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMice platform.   Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will have full access to Biocytogen’s RenMice platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets.   Merck KGaA, Darmstadt, Germany will be responsible for all clinical development, manufacturing, and commerc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters